Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Final analysis of the prospective, observational REFINE study

被引：1

作者：

Kim, Y. J. ^{[1
]}

Kurosaki, M. ^{[2
]}

Numata, K. ^{[3
]}

Lim, H. Y. ^{[4
]}

Ikeda, M. ^{[5
]}

Kudo, M. ^{[6
]}

Huang, Y-H. ^{[7
]}

Shao, G. ^{[8
]}

Kato, N. ^{[9
]}

Kim, D-Y. ^{[10
]}

Cho, S-B. ^{[11
]}

Hsu, C-H. ^{[12
]}

Lin, S-M. ^{[13
]}

Jeng, L-B. ^{[14
]}

Kuo, K-K. ^{[15
]}

Mao, Y. ^{[16
]}

Chewaskulyong, B. ^{[17
]}

Khan, J. ^{[18
]}

Ozgurdal, K. ^{[19
]}

Qin, S. ^{[20
]}

机构：

[1] Seoul Natl Univ Hosp, Liver Canc Ctr, Seoul, South Korea

[2] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, Tokyo, Japan

[3] Yokohama City Univ, Med Ctr, Gastroenterol Ctr, Yokohama, Kanagawa, Japan

[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[5] Natl Canc Ctr Hosp East, Hepatobiliary & Pancreat Oncol Dept, Kashiwa, Chiba, Japan

[6] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan

[7] Taipei Vet Gen Hosp, Div Gastrotenterol & Hepatol, Taipei, Taiwan

[8] Zhejiang Canc Hosp, Canc Res Inst, Dept Intervent, Hangzhou, Peoples R China

[9] Chiba Univ Hosp, Dept Gastroenterol, Chiba, Japan

[10] Severance Hosp, Dept Internal Med, Seoul, South Korea

[11] Chonnam Natl Univ, Hwasun Hosp, Hepatol Internal Med, Hwasun, South Korea

[12] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[13] Linkou Chang Gung Mem Hosp, Chang Gung Med Fdn, Dept Gastroenterol & Hepatol, Taoyuan, Taiwan

[14] China Med Univ Hosp, Dept Surg, Taichung, Taiwan

[15] Kaohsiung Med Univ, Chung Ho Mem Hosp, Div Gen & Digest Surg, Kaohsiung, Taiwan

[16] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Canc Hosp, Dept Liver Surg, Beijing, Peoples R China

[17] Maharaj Nakorn Chiang Mai Hosp, Fac Med, Chiang Mai, Thailand

[18] Bayer PLC, Oncol, Reading, Berks, England

[19] Bayer Consumer Care AG, Med Dept, Basel, Switzerland

[20] Nanjing Bayi Hosp, Chinese Peoples Liberat Army Canc Ctr, Nanjing, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.10.109

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

73MO

引用

页码：S1459 / S1460

页数：3

共 50 条

[21] Safety and efficacy of atezolizumab (Atezo) plus bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): A prospective, multicenter, observational study (ELIXIR) - A preliminary analysis
Ikeda, M.
Kato, N.
Kagawa, T.
Yamashita, T.
Moriguchi, M.
Nakamura, S.
Sawada, K.
Iijima, H.
Kamoshida, T.
Nakao, K.
Ohkawa, K.
Sugimoto, R.
Takehara, T.
Harada, M.
Yamamoto, Y.
Ito, T.
Kudo, M.
Kokudo, N.
Yamamoto, K.
Furuse, J.
ANNALS OF ONCOLOGY, 2022, 33 : S1467 - S1467
[22] Safety and efficacy of atezolizumab (Atezo) plus bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Kuzuya, T.
Yamashita, T.
Takehara, T.
Aikata, H.
Kato, N.
Hiasa, Y.
Nakamura, S.
Morimoto, N.
Moriguchi, M.
Ikeda, M.
Inoue, J.
Tani, J.
Ueno, Y.
Chayama, K.
Tateishi, R.
Kawamura, Y.
Furuse, J.
Kudo, M.
Yamamoto, K.
Kokudo, N.
ANNALS OF ONCOLOGY, 2023, 34 : S1531 - S1532
[23] Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan
Junji Furuse
Namiki Izumi
Kenta Motomura
Yoshitaka Inaba
Yoshio Katamura
Yasuteru Kondo
Kazuhisa Yabushita
Katsuaki Motoyoshi
Masatoshi Kudo
Drugs - Real World Outcomes, 2023, 10 : 195 - 205
[24] Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan
Furuse, Junji
Izumi, Namiki
Motomura, Kenta
Inaba, Yoshitaka
Katamura, Yoshio
Kondo, Yasuteru
Yabushita, Kazuhisa
Motoyoshi, Katsuaki
Kudo, Masatoshi
DRUGS-REAL WORLD OUTCOMES, 2023, 10 (02) : 195 - 205
[25] LENVATINIB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN REAL-WORLD PRACTICE - MULTICENTER ANALYSIS OF PROGNOSTIC FACTORS
Hiraoka, Atsushi
Kumada, Takashi
Atsukawa, Masanori
Hirooka, Masashi
Ishikawa, Toru
Kunihiko, Tsuji
Takaguchi, Koichi
Kariyama, Kazuya
Itobayashi, Ei
Tajiri, Kazuto
Shimada, Noritomo
Shibata, Hiroshi
Ochi, Hironori
Tada, Toshifumi
Toyoda, Hidenori
Nouso, Kazuhiro
Tsutsui, Akemi, Sr.
Nagano, Takuya
Itokawa, Norio
Hayama, Korenobu
Imai, Michitaka
Joko, Kouji
Koizumi, Yohei
Hiasa, Yoichi
Michitaka, Kojiro
Kudo, Masatoshi
HEPATOLOGY, 2019, 70 : 217A - 218A
[26] Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States
Finn, Richard S.
Iyer, Renuka
Kalman, Richard S.
Parikh, Neehar D.
Cabrera, Roniel
Babajanyan, Svetlana
Kaseb, Ahmed O.
JOURNAL OF HEPATOCELLULAR CARCINOMA, 2025, 12 : 231 - 246
[27] Real-world registry of patients with unresectable hepatocellular carcinoma: The OREIOS study.
Chan, Stephen Lam
Ryu, Min-Hee
Waked, Imam
Shao, Yu Yun
Tai, Wai Meng David
Breder, Valeriy
Alolayan, Ashwaq
Ganguly, Sandip
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS618 - TPS618
[28] Real-world experience of regorafenib in patients with hepatocellular carcinoma: A multicenter United Kingdom study
Ross, Paul J.
Ma, Yuk Ting
Palmer, Daniel H.
Lythgoe, Mark Peter
Merrick, Sophie
Samson, Adel
Rao, Ankit Rohit
Basu, Bristi
Prasad, Debi
Dhillon, Tony
Lau, David
Darby, Suzanne
Orr, James
Margetts, Jane
Hubner, Richard
Baijal, Shobhit
Sharma, Rohini
Faluyi, Olusola Olusesan
Lee, Lennard
Thillai, Kiruthikah
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[29] Immunotherapy combination with regorafenib for refractory hepatocellular carcinoma: A real-world study
Tu, Xinyue
Yang, Jing
Zheng, Yingbin
Liang, Chen
Tao, Qiang
Tang, Xiang
Liu, Zonghao
Jiang, Lingmin
He, Zhaoqian
Xie, Feihu
Zheng, Yun
INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 113
[30] Regorafenib combined with a PD-1 inhibitor in the second-line setting for unresectable hepatocellular carcinoma in real-world practice
Bi, Huaqiang
Pei, Jun
Ma, Kuansheng
Zhang, Yanling
Aprile, Giuseppe
Moris, Dimitrios
Mendez-Sanchez, Nahum
Samant, Hrishikesh
Sun, Ximin
Xia, Feng
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (01) : 368 - 376

← 1 2 3 4 5 →